DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tv6tkx/adc_contract) has announced the addition of the "ADC Contract Manufacturing Market (2nd edition), 2015-2025" report to their offering.
Antibody Drug Conjugates (ADCs) are a new class of therapeutic drugs consisting of a cytotoxic drug linked to a monoclonal antibody. These novel conjugates are believed to be very effective and efficient in treatment of a disease. However, manufacturing such highly potent toxic molecules is accompanied with several known and unknown challenges.
In-house manufacturing of ADCs is rare primarily because of the complex nature of these molecules. Their manufacturing requires both clean room biologic and high containment cytotoxic facilities. This combination is rare and difficult to achieve, requiring significant capital investment.
Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk. Even the leading technology providers, including Seattle Genetics and ImmunoGen, are dependent on contract manufacturers to supply the components. Despite the fact that some developers (e.g. Roche) have recently announced their plans to build in-house facilities, the trend of outsourcing is likely to continue for at least the coming decade.
It is worth highlighting there has been a surge in investment activity for facility expansions by a number of CMOs. The concept of one-stop-shop is also gaining traction as CMOs have collaborated with one another in an effort to cater to the increasing demand and to streamline the manufacturing process under one umbrella. Although there are two marketed ADCs till date, a rich and extensive pipeline presents a very big opportunity for the contract manufacturers.
The report provides an extensive study of the contract manufacturing opportunity for the emerging class of ADCs. The report covers various aspects, such as identifying CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities.
The base year for the report is 2015. The report provides short-mid term and long term market forecasts for the period 2015 - 2020 and 2020 - 2025, respectively. We have discussed, in detail, the key drivers behind the growth of the ADC contract manufacturing market. The research, analysis and insights presented in this report are backed by a comprehensive survey on ADC manufacturing capabilities of several CMOs.
In addition, we interviewed important stakeholders to solicit their opinions around the future opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Piramal Healthcare, Pierre Fabre, Catalent, Lonza and BSP Pharmaceuticals.
Key Topics Covered:
2. Executive Summary
4. ADC Therapeutics: Development Overview
5. Manufacturing of ADCs: A Market Overview
6. CMOs: Worldwide Landscape
7. Profiles of Leading Companies
8. Recent Developments
9. Market Size and Forecast
10. SWOT Analysis
12. Interview Transcripts
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organisations
Companies Mentioned - 35 of the 100+ Companies
- AAIPharma Services Corp
- AMRI Global
- Aspyrian Therapeutics
- Astellas Pharma/Agensys
- Baxter BioPharma Solutions
- Bayer Healthcare
- Cambrex Corporation
- CARBOGEN AMCIS
- DSM Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Heidelberg Pharma
- Heraeus Precious Metals
- Mersana Therapeutics
- National Cancer Institute
- National Research Council Canada
- NBE Therapeutics
- Pierre Fabre
- Redwood Bioscience
- SafeBridge Consultants
For more information visit http://www.researchandmarkets.com/research/tv6tkx/adc_contract